BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:INR731 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of INR731\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07570979-11259@assetmemo.bio
DTSTAMP:20261121T005645Z
DTSTART;VALUE=DATE:20300603
DTEND;VALUE=DATE:20300604
SUMMARY:INR731: Phase 1 readout est. (NCT07570979)
DESCRIPTION:INR731\, phase 1\, Prostate Cancer.\nStudy: A Study to Investig
 ate the Safety and Tolerability of Oral INR731 Single Agent or in Combinat
 ion With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metas
 tatic Prostate Cancer\nEstimated primary completion: 3 June 2030. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/inr731#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07570979
URL:https://assetmemo.bio/drug/inr731#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
